Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04144608

Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer Clinical Trial

Official title:
A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Clinical Trial Summary

The aim of the study was to investigate the safety and efficacy of Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04144608
Study type Interventional
Source Hunan Province Tumor Hospital
Contact
Status Completed
Phase Phase 2
Start date January 16, 2019
Completion date July 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03326752 - Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC Phase 1
Completed NCT02157883 - Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Phase 1
Completed NCT00072631 - Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT02163733 - Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06107374 - Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG Phase 2
Completed NCT01802632 - AZD9291 First Time In Patients Ascending Dose Study Phase 1/Phase 2
Recruiting NCT06406166 - Lifei Xiaoji Wan in Treatment of Advanced NSCLC N/A
Terminated NCT04785365 - Long-Term Follow-Up Study of Patients Receiving ATL001 Phase 2
Recruiting NCT04032847 - ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC Phase 1/Phase 2
Completed NCT01631136 - Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer Phase 3
Recruiting NCT04239443 - Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer Phase 2
Completed NCT03452150 - D-0316 First Time in Patients Ascending Dose Study Phase 1
Not yet recruiting NCT04755738 - Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer Phase 2
Completed NCT03652857 - Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Completed NCT03351361 - Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients Phase 3
Completed NCT02407327 - Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Active, not recruiting NCT02143466 - AZD9291 in Combination With Ascending Doses of Novel Therapeutics Phase 1
Recruiting NCT05004974 - Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT05777603 - Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT04886401 - Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC